Literature DB >> 29125427

The surgical treatment of metastatic spine tumors within the intramedullary compartment.

Ben A Strickland, Ian E McCutcheon, Indro Chakrabarti, Laurence D Rhines, Jeffrey S Weinberg.   

Abstract

OBJECTIVE Metastasis to the spinal cord is rare, and optimal management of this disease is unclear. The authors investigated this issue by analyzing the results of surgical treatment of spinal intramedullary metastasis (IM) at a major cancer center. METHODS The authors retrospectively reviewed the medical records of 13 patients who underwent surgery for IM. Patients had renal cell carcinoma (n = 4), breast carcinoma (n = 3), melanoma (n = 2), non-small cell lung cancer (n = 1), sarcoma (n = 1), adenoid cystic carcinoma (n = 1), and cervical cancer (n = 1). Cerebrospinal fluid was collected before surgery in 11 patients, and was negative for malignant cells, as was MRI of the neuraxis. Eleven patients presented with neurological function equivalent to Frankel Grade D. RESULTS Radiographic gross-total resection was achieved in 9 patients, and tumor eventually recurred locally in 3 of those 9 (33%). Leptomeningeal disease was diagnosed in 4 patients after surgery. In the immediate postoperative period, neurological function in 6 patients deteriorated to Frankel Grade C. At 2 months, only 2 patients remained at Grade C, 8 were at Grade D, and 1 had improved to Grade E. One patient developed postoperative hematoma resulting in Frankel Grade A. Radiotherapy was delivered in 8 patients postoperatively. The median survival after spine surgery was 6.5 months. Three patients are still living. CONCLUSIONS Surgery was performed as a last option to preserve neurological function in patients with IM. In most patients, neurological function returned during the immediate postoperative period and was preserved for the patients' remaining lifetime. The data suggest that surgery can be effective in preventing further decline in selected patients with progressive neurological deficit.

Entities:  

Keywords:  GTR = gross-total resection; IM = intramedullary metastasis; KPS = Karnofsky Performance Scale; LMD = leptomeningeal disease; SRS = stereotactic radiosurgery; STR = subtotal resection; WBRT = whole-brain radiotherapy; intramedullary metastasis; oncology; spine surgery; surgical technique

Mesh:

Year:  2017        PMID: 29125427     DOI: 10.3171/2017.5.SPINE161161

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  5 in total

1.  Prognostic significance of pretreatment plasma D-dimer levels in patients with spinal chordoma: a retrospective cohort study.

Authors:  Bo Li; Hao Zhang; Pingting Zhou; Jiaxiang Yang; Haifeng Wei; Xinghai Yang; Cheng Yang; Zhipeng Wu; Jianru Xiao
Journal:  Eur Spine J       Date:  2019-01-25       Impact factor: 3.134

2.  Image-Guided Robotic Radiosurgery for the Management of Intramedullary Spinal Cord Metastases-A Multicenter Experience.

Authors:  Felix Ehret; Carolin Senger; Markus Kufeld; Christoph Fürweger; Melina Kord; Alfred Haidenberger; Paul Windisch; Daniel Rueß; David Kaul; Maximilian Ruge; Christian Schichor; Jörg-Christian Tonn; Alexander Muacevic
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

3.  Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.

Authors:  Marion Tonneau; Raphaëlle Mouttet-Audouard; Florence Le Tinier; Xavier Mirabel; David Pasquier
Journal:  BMC Cancer       Date:  2021-10-30       Impact factor: 4.430

4.  Clinical Features, Treatments, and Prognosis of Intramedullary Spinal Cord Metastases From Lung Cancer: A Case Series and Systematic Review.

Authors:  Liang Wu; Li'ao Wang; Jun Yang; Wenqing Jia; Yulun Xu
Journal:  Neurospine       Date:  2022-02-03

Review 5.  The Role of Surgery in Spinal Intradural Metastases from Renal Cell Carcinoma: A Literature Review.

Authors:  Sergio Corvino; Giuseppe Mariniello; Domenico Solari; Jacopo Berardinelli; Francesco Maiuri
Journal:  Cancers (Basel)       Date:  2022-03-21       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.